MK-677 Research

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J · J Clin Endocrinol Metab (2001)

Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.

Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M, Mendel CM, Caufriez A, Leproult R · J Clin Endocrinol Metab (1996)

Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.

Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM · J Clin Endocrinol Metab (1996)

Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677.

Svensson J, Carlsson B, Carlsson LM, Jansson JO, Bengtsson BA · Clin Endocrinol (Oxf) (1999)

Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.

Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D · J Bone Miner Res (1999)

MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.

Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y · Arch Gerontol Geriatr (2011)

Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.

Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D · J Bone Miner Res (1998)

Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.

Codner E, Cassorla F, Tiulpakov AN, Mericq MV, Avila A, Pescovitz OH · Clin Pharmacol Ther (2001)

Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.

Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML · Neurology (2008)

Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.

In plain English: Over 12 months, the ghrelin mimetic MK-677 enhanced pulsatile growth hormone secretion, significantly increased fat-free mass, and was generally well tolerated ... Increased fat-free mass did not result in changes in strength or function.

Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO. · Ann Intern Med (2008)

Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study.

In plain English: MK-0677 increased serum IGF-1 levels with minimal adverse effects in hemodialysis subjects. Studies are needed to evaluate whether long-term therapy ... improves PEW, lean body mass, physical strength, quality of life and survival.

Campbell GA, Patrie JT, Gaylinn BD, Thorner MO, Bolton WK. · Nephrol Dial Transplant (2018)

MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.

In plain English: MK-677 reverses diet-induced nitrogen wasting, suggesting that if these short-term anabolic effects are maintained in patients who are catabolic ... it may be useful in treating catabolic conditions.

Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR. · J Clin Endocrinol Metab (1998)

Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.

In plain English: 2-month treatment with MK-677 in healthy obese males caused a sustained increase in serum levels of GH, IGF-I, and IGF-binding protein-3 ... an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks.

Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. · J Clin Endocrinol Metab (1998)

MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer's Disease.

In plain English: Activation of the ghrelin receptor with MK-0677 inhibited the Aβ burden, neuroinflammation, and neurodegeneration, which suggested that MK-0677 might have potential as a treatment of the early phase of AD.

Jeong YO, Shin SJ, Park JY, Ku BK, Song JS, Kim JJ, Jeon SG, Lee SM, Moon M. · Int J Mol Sci (2018)

The Safety and Efficacy of Growth Hormone Secretagogues.

In plain English: To date, few long-term, rigorously controlled studies have examined the efficacy and safety of GHSs ... the safety of these compounds with long-term use, including evaluation of cancer incidence and mortality, is needed.

Sigalos JT, Pastuszak AW. · Sex Med Rev (2018)

The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms.

In plain English: These moderate changes in the proportion non-22K GH isoforms are likely of small importance for the clinical response to MK-677 treatment.

Svensson J, Boguszewski CL, Shibata F, Carlsson B, Carlsson LM, Bengtsson BA. · Growth Horm IGF Res (2003)

Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor.

In plain English: The non-peptidyl synthetic GHS-R1a agonist, MK0677 ... increased GHS-R1a-mediated intracellular calcium influx.

Schellekens H, McNamara O, Dinan TG, McCarthy JV, McGlacken GP, Cryan JF. · J Pharm Pharmacol (2013)